Acidic Nanoparticles Restore Lysosomal Acidification and Rescue Metabolic Dysfunction in Pancreatic β-Cells under Lipotoxic Conditions
Source abstract
Abstract
Type 2 diabetes (T2D), a prevalent metabolic disorder lacking effective treatments, is associated with lysosomal acidification dysfunction, as well as autophagic and mitochondrial impairments. Here, we report a series of biodegradable poly(butylene tetrafluorosuccinate- co -succinate) polyesters, comprising a 1,4-butanediol linker and varying ratios of tetrafluorosuccinic acid (TFSA) and succinic acid as components, to engineer lysosome-acidifying nanoparticles (NPs). The synthesized NPs are spherical with diameters of ≈100 nm and have low polydispersity and good stability. Notably, TFSA NPs, which are composed entirely of TFSA, exhibit the strongest degradation capability and superior acidifying properties. We further reveal significant downregulation of lysosomal vacuolar (H+)-ATPase subunits, which are responsible for maintaining lysosomal acidification, in human T2D pancreatic islets, INS-1 β-cells under chronic lipotoxic conditions, and pancreatic tissues of high-fat-diet (HFD) mice. Treatment with TFSA NPs restores lysosomal acidification, autophagic function, and mitochondrial activity, thereby improving the pancreatic function in INS-1 cells and HFD mice with lipid overload. Importantly, the administration of TFSA NPs to HFD mice reduces insulin resistance and improves glucose clearance. These findings highlight the therapeutic potential of lysosome-acidifying TFSA NPs for T2D.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Endoplasmic Reticulum Stress and Disease · Calcium signaling and nucleotide metabolism
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Lee Kong Chian School of Medicine, Nanyang Technological University
College of Biological Sciences
University of Minnesota
Meinig School of Biomedical Engineering
Cornell University
Department of Chemistry
Boston University
Division of Endocrinology, Department of Medicine
David Geffen School of Medicine, University of California, Los Angeles
Department of Molecular and Medical Pharmacology
University of California, Los Angeles
Department of Biomedical Engineering
Funding
Momental Foundation · Nanyang Technological University
References (100+)
Show source-provided references
1. 10.2147/DMSO.S31989510.2147/DMSO.S319895 ↗
2. International Diabetes Federation, IDF Diabetes Atlas, 2021.
3. 10.1016/j.pcd.2023.03.00510.1016/j.pcd.2023.03.005 ↗
4. 10.1016/j.cmet.2021.12.01210.1016/j.cmet.2021.12.012 ↗
5. 10.1159/00048052510.1159/000480525 ↗
6. 10.1038/nrendo.2013.25610.1038/nrendo.2013.256 ↗
7. 10.1007/s00125-017-4342-z10.1007/s00125-017-4342-z ↗
8. 10.1016/j.metabol.2015.10.01410.1016/j.metabol.2015.10.014 ↗
9. 10.1080/14656566.2021.199941310.1080/14656566.2021.1999413 ↗
10. 10.5114/aoms.2015.5330410.5114/aoms.2015.53304 ↗
11. 10.1016/S0140-6736(12)61267-710.1016/S0140-6736(12)61267-7 ↗
12. 10.2147/DMSO.S700410.2147/DMSO.S7004 ↗
13. 10.1517/14656566.7.8.105510.1517/14656566.7.8.1055 ↗
14. 10.1038/nrd447710.1038/nrd4477 ↗
15. 10.1016/j.tem.2020.02.00110.1016/j.tem.2020.02.001 ↗
16. 10.1002/advs.20210246610.1002/advs.202102466 ↗
17. 10.1016/j.drudis.2022.10339310.1016/j.drudis.2022.103393 ↗
18. 10.1186/s12951-015-0136-y10.1186/s12951-015-0136-y ↗
19. 10.1074/jbc.M111.24241210.1074/jbc.M111.242412 ↗
20. 10.2337/db16-100910.2337/db16-1009 ↗
21. 10.1096/fj.201801292R10.1096/fj.201801292R ↗
22. 10.1002/adhm.20180151110.1002/adhm.201801511 ↗
23. 10.3390/cells905113110.3390/cells9051131 ↗
24. 10.1089/ars.2022.001610.1089/ars.2022.0016 ↗
25. 10.1016/j.jmb.2019.07.03010.1016/j.jmb.2019.07.030 ↗
26. 10.1083/jcb.20151104210.1083/jcb.201511042 ↗
27. 10.1186/s40035-023-00362-010.1186/s40035-023-00362-0 ↗
28. 10.36069/JoLS/2020120410.36069/JoLS/20201204 ↗
29. Carlson, J. G.; Rotto, N. T.; Anderson, J. T.; Spawn, C.L.; Blagev, A. V. Carboxylic acid functional polyurethane polymers and blends thereof used in magnetic recording media. WO1997023526A11996.
30. 10.1097/00002480-199407000-0012110.1097/00002480-199407000-00121 ↗
31. 10.1093/nar/gky103310.1093/nar/gky1033 ↗
32. 10.1295/polymj.7.46010.1295/polymj.7.460 ↗
33. 10.1039/c3nr00114h10.1039/c3nr00114h ↗
34. 10.1039/D1TB00559F10.1039/D1TB00559F ↗
35. Tyagi S. · Res. Rev.: J. Pharm. Nanotechnol. · 2016 · 4 · 2347
36. Chime S. A. · 2014
37. 10.1016/0166-6622(86)80340-710.1016/0166-6622(86)80340-7 ↗
38. 10.1016/j.ajps.2015.09.00410.1016/j.ajps.2015.09.004 ↗
39. 10.1074/jbc.M110.20029510.1074/jbc.M110.200295 ↗
40. 10.1186/s13578-022-00836-010.1186/s13578-022-00836-0 ↗
41. 10.36069/jols/2020120110.36069/jols/20201201 ↗
42. 10.1073/pnas.190367811610.1073/pnas.1903678116 ↗
43. 10.1016/j.bbrc.2011.08.04110.1016/j.bbrc.2011.08.041 ↗
44. 10.1016/j.abb.2022.10911610.1016/j.abb.2022.109116 ↗
45. 10.1016/j.mce.2004.04.01710.1016/j.mce.2004.04.017 ↗
46. 10.3389/fcell.2020.59076310.3389/fcell.2020.590763 ↗
47. 10.1080/19382014.2023.226772510.1080/19382014.2023.2267725 ↗
48. 10.1038/s41467-023-38165-610.1038/s41467-023-38165-6 ↗
49. 10.14573/altex.2010.2.10510.14573/altex.2010.2.105 ↗
50. 10.1038/s41580-020-00317-710.1038/s41580-020-00317-7 ↗
51. 10.1152/ajpcell.00466.202010.1152/ajpcell.00466.2020 ↗
52. 10.1080/15548627.2021.201600410.1080/15548627.2021.2016004 ↗
53. 10.1080/15548627.2020.179728010.1080/15548627.2020.1797280 ↗
54. 10.1038/embor.2013.16810.1038/embor.2013.168 ↗
55. 10.1016/j.redox.2021.10202610.1016/j.redox.2021.102026 ↗
56. 10.3389/fnut.2021.66383810.3389/fnut.2021.663838 ↗
57. 10.2337/diabetes.53.suppl_3.s21510.2337/diabetes.53.suppl_3.s215 ↗
58. 10.1172/JCI1076110.1172/JCI10761 ↗
59. Wilcox G. · Clin. Biochem. Rev. · 2005 · 26 · 19
60. 10.1371/journal.pone.020518010.1371/journal.pone.0205180 ↗
61. 10.1074/jbc.M31149320010.1074/jbc.M311493200 ↗
62. 10.1038/s12276-020-0456-310.1038/s12276-020-0456-3 ↗
63. 10.1016/j.ebiom.2020.10279710.1016/j.ebiom.2020.102797 ↗
64. 10.1016/j.ebiom.2020.10282410.1016/j.ebiom.2020.102824 ↗
65. 10.4103/1673-5374.39097910.4103/1673-5374.390979 ↗
66. 10.1007/s00125-021-05387-610.1007/s00125-021-05387-6 ↗
67. 10.1152/ajpendo.00151.202110.1152/ajpendo.00151.2021 ↗
68. 10.1073/pnas.190367811610.1073/pnas.1903678116 ↗
69. 10.1038/s41467-019-11170-410.1038/s41467-019-11170-4 ↗
70. 10.1038/414807a10.1038/414807a ↗
71. 10.1042/BJ2008138610.1042/BJ20081386 ↗
72. 10.3390/ijms2204150910.3390/ijms22041509 ↗
73. 10.1016/j.redox.2017.01.01310.1016/j.redox.2017.01.013 ↗
74. 10.1074/jbc.M20970920010.1074/jbc.M209709200 ↗
75. 10.2337/db07-178110.2337/db07-1781 ↗
76. 10.1210/endo.140.8.690810.1210/endo.140.8.6908 ↗
77. Valdez, I. A.; Palavicini, J. P.; Bakewell, T. M.; Fourcaudot, M.; Ayala, I.; Xu, Z.; Khattab, A.; Han, X.; Shannon, C. E.; Norton, L. Persistent Inflammatory Lipotoxicity Impedes Pancreatic β-cell Function in Diet-Induced Obese Mice Despite Correction of Glucotoxicity bioRxiv 2022, 494168.10.1101/2022.05.31.494168.10.1101/2022.05.31.494168 ↗
78. 10.1152/ajpendo.00088.202010.1152/ajpendo.00088.2020 ↗
79. 10.1021/acs.iecr.9b0200310.1021/acs.iecr.9b02003 ↗
80. 10.1186/s12974-023-02866-y10.1186/s12974-023-02866-y ↗
81. 10.1002/advs.20220721410.1002/advs.202207214 ↗
82. 10.1002/btm2.1035010.1002/btm2.10350 ↗
83. Miladi K. · 2016 · 1710.1007/978-3-319-41421-8_2 ↗
84. 10.1021/acsbiomedchemau.2c0004810.1021/acsbiomedchemau.2c00048 ↗
85. Lo C. H. · 2021 · 121
86. 10.1016/j.jmb.2017.08.00910.1016/j.jmb.2017.08.009 ↗
87. 10.1080/15384047.2023.217669210.1080/15384047.2023.2176692 ↗
88. 10.1038/s41467-022-32346-510.1038/s41467-022-32346-5 ↗
89. 10.1007/978-1-4939-3578-9_510.1007/978-1-4939-3578-9_5 ↗
90. 10.3390/brainsci1309131810.3390/brainsci13091318 ↗
91. 10.1016/j.jpha.2023.06.01110.1016/j.jpha.2023.06.011 ↗
92. 10.1093/nar/gkac19410.1093/nar/gkac194 ↗
93. 10.1093/nar/28.1.2710.1093/nar/28.1.27 ↗
94. 10.1038/7555610.1038/75556 ↗
95. 10.1016/j.xpro.2020.10013210.1016/j.xpro.2020.100132 ↗
96. 10.1038/s41388-021-01832-310.1038/s41388-021-01832-3 ↗
97. 10.1016/j.bbrc.2017.02.10210.1016/j.bbrc.2017.02.102 ↗
98. 10.1016/j.acthis.2017.03.00110.1016/j.acthis.2017.03.001 ↗
99. 10.1016/j.xpro.2022.10140110.1016/j.xpro.2022.101401 ↗
100. 10.1083/jcb.20160303910.1083/jcb.201603039 ↗